Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanomaJ Immunother Cancer 2021 Nov 01;9(11)e003675, WJ Storkus, D Maurer, Y Lin, F Ding, A Bose, D Lowe, A Rose, M DeMark, L Karapetyan, JL Taylor, M Chelvanambi, RJ Fecek, JN Filderman, TJ Looney, L Miller, E Linch, GM Lowman, P Kalinski, LH Butterfield, A Tarhini, H Tawbi, JM Kirkwood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.